Invesco Ltd. Grows Holdings in Vaxart, Inc. (NASDAQ:VXRT)

Invesco Ltd. lifted its stake in Vaxart, Inc. (NASDAQ:VXRT) by 48.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 75,798 shares of the biotechnology company’s stock after acquiring an additional 24,803 shares during the quarter. Invesco Ltd.’s holdings in Vaxart were worth $50,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC lifted its stake in Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 35,213 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Vaxart during the 4th quarter worth approximately $129,000. Finally, Geode Capital Management LLC boosted its position in Vaxart by 15.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock valued at $2,160,000 after buying an additional 346,725 shares during the period. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Vaxart Trading Down 7.7 %

Shares of VXRT stock opened at $0.42 on Tuesday. Vaxart, Inc. has a 12 month low of $0.29 and a 12 month high of $1.07. The company has a market cap of $94.73 million, a P/E ratio of -1.01 and a beta of 1.27. The firm has a fifty day moving average price of $0.43 and a 200 day moving average price of $0.60.

Vaxart (NASDAQ:VXRT) last released its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. On average, equities analysts forecast that Vaxart, Inc. will post -0.39 EPS for the current year.

Analysts Set New Price Targets

Separately, B. Riley decreased their price target on shares of Vaxart from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Thursday, March 27th.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.